Sara Isabel Pai

Sara Isabel Pai, MD, PhD, is a Professor at Yale School of Medicine with primary appointments in the Department of Surgery and Otolaryngology. She is a surgical oncologist specializing in HPV-associated head and neck cancers, thyroid, and parathyroid disorders. Her research integrates surgical practice with immunology to develop novel immunotherapies.

Education:

• PhD in Cancer Immunology and Vaccines, Johns Hopkins University School of Medicine
• MD, Johns Hopkins University School of Medicine
• Residency in Otolaryngology-Head and Neck Surgery, Johns Hopkins Hospital

Research Interests:
Dr. Pai's research focuses on understanding how human papillomavirus (HPV) evades the immune system and developing strategies to reactivate immune responses against HPV-related cancers. Her work bridges basic immunology, translational research, and clinical application, particularly in the context of head and neck oncology. She has pioneered studies leading to FDA orphan drug designation for pembrolizumab in recurrent respiratory papillomatosis.

Publication Trends:
Her recent work emphasizes clinical immunotherapy trials, HPV-related cancer biology, and translational research. Articles reflect a strong focus on immune evasion mechanisms, therapeutic reactivation, regulatory milestones, and multidisciplinary cancer care. The publications span high-impact journals and highlight leadership in both research and academic service.

Scientific Awards:

• FDA Orphan Drug Designation for pembrolizumab in treating recurrent respiratory papillomatosis (RRP)

Advising and Grants:
While specific advisees are not listed, Dr. Pai is committed to training the next generation of surgeon-scientists. She leads multiple investigator-initiated and industry-sponsored clinical trials, indicating significant grant and research funding support. Her role as Senior Editor for Cancer Research further underscores her leadership in the scientific community.

Labs and Teams:
Dr. Pai is affiliated with the Yale Cancer Center and Smilow Cancer Hospital. She collaborates with the Human Papillomavirus (HPV) Working Group and is involved in regional translational research symposia, indicating active participation in collaborative research networks and interdisciplinary teams focused on head and neck oncology.